Kestra Private Wealth Services LLC lessened its position in shares of Cardinal Health, Inc. (NYSE:CAH – Free Report) by 22.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 18,682 shares of the company’s stock after selling 5,281 shares during the period. Kestra Private Wealth Services LLC’s holdings in Cardinal Health were worth $4,157,000 at the end of the most recent reporting period.
Other institutional investors have also recently made changes to their positions in the company. Chicago Partners Investment Group LLC lifted its stake in shares of Cardinal Health by 26.3% during the 3rd quarter. Chicago Partners Investment Group LLC now owns 1,868 shares of the company’s stock valued at $466,000 after buying an additional 389 shares in the last quarter. Rakuten Investment Management Inc. grew its stake in Cardinal Health by 9.1% in the 3rd quarter. Rakuten Investment Management Inc. now owns 41,851 shares of the company’s stock valued at $9,371,000 after buying an additional 3,480 shares in the last quarter. Provenance Wealth Advisors LLC grew its stake in Cardinal Health by 1,940.0% in the 3rd quarter. Provenance Wealth Advisors LLC now owns 408 shares of the company’s stock valued at $91,000 after buying an additional 388 shares in the last quarter. First Nebraska Trust Co bought a new stake in Cardinal Health during the 3rd quarter valued at $18,218,000. Finally, Next Level Wealth Planning LLC bought a new stake in Cardinal Health during the 3rd quarter valued at $44,000. Hedge funds and other institutional investors own 87.17% of the company’s stock.
Key Cardinal Health News
Here are the key news stories impacting Cardinal Health this week:
- Positive Sentiment: Adjusted EPS was $3.26, above the roughly $2.94 analyst consensus and up 28% year over year. Revenue rose 5% to $67.5 billion, also topping expectations. Cardinal Health Q1 results and outlook
- Positive Sentiment: Management raised fiscal 2027 adjusted EPS guidance to $12.80–$13.00, signaling confidence in continued growth. Robust pharmaceutical sales helped drive the quarter. Q1 earnings beat on pharmaceutical strength
- Positive Sentiment: Cardinal completed a $500 million share-repurchase program during the quarter. The results also drew favorable analyst attention, including a price-target increase. Analyst raises price target
- Neutral Sentiment: The shares also advanced while the broader market was under pressure, suggesting the earnings and guidance news were a company-specific catalyst. Cardinal gains amid broader market declines
- Negative Sentiment: Management noted modest commodity and petroleum-related pressure in medical distribution, a potential headwind against otherwise healthy demand. Demand and commodity pressures
Insider Transactions at Cardinal Health
In related news, CEO Deborah Weitzman sold 7,354 shares of the stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $235.45, for a total value of $1,731,499.30. Following the sale, the chief executive officer owned 77,901 shares in the company, valued at approximately $18,341,790.45. This trade represents a 8.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Jason Hollar sold 80,000 shares of the stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $235.74, for a total value of $18,859,200.00. Following the completion of the sale, the chief executive officer owned 235,132 shares in the company, valued at $55,430,017.68. This trade represents a 25.39% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 210,271 shares of company stock valued at $49,626,657. Corporate insiders own 0.12% of the company’s stock.
Analyst Upgrades and Downgrades
CAH has been the topic of several recent research reports. Citigroup increased their target price on Cardinal Health from $265.00 to $280.00 and gave the stock a “buy” rating in a research report on Wednesday, August 12th. Morgan Stanley lifted their price target on Cardinal Health from $265.00 to $286.00 and gave the company an “overweight” rating in a research report on Friday, October 30th. Mizuho set a $290.00 price objective on Cardinal Health in a research note on Thursday. Wall Street Zen raised Cardinal Health from a “buy” rating to a “strong-buy” rating in a report on Sunday, October 25th. Finally, Wells Fargo & Company raised their target price on Cardinal Health from $245.00 to $277.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 12th. Sixteen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $271.31.
Check Out Our Latest Stock Analysis on Cardinal Health
Cardinal Health Trading Up 2.4%
Shares of NYSE:CAH opened at $268.10 on Friday. The company has a 50 day moving average of $239.73 and a 200 day moving average of $223.24. The stock has a market cap of $62.08 billion, a P/E ratio of 37.08, a P/E/G ratio of 1.57 and a beta of 0.53. Cardinal Health, Inc. has a 12 month low of $180.45 and a 12 month high of $286.29.
Cardinal Health (NYSE:CAH – Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported $3.26 earnings per share for the quarter, topping analysts’ consensus estimates of $2.94 by $0.32. Cardinal Health had a net margin of 0.67% and a negative return on equity of 98.53%. The business had revenue of $67.51 billion for the quarter, compared to analyst estimates of $66.67 billion. During the same quarter in the prior year, the firm posted $2.55 EPS. Cardinal Health’s revenue was up 5.5% on a year-over-year basis. On average, equities analysts forecast that Cardinal Health, Inc. will post 12.55 earnings per share for the current fiscal year.
Cardinal Health Dividend Announcement
The company also recently declared a quarterly dividend, which was paid on Thursday, October 15th. Stockholders of record on Thursday, October 1st were issued a $0.5158 dividend. The ex-dividend date of this dividend was Thursday, October 1st. This represents a $2.06 annualized dividend and a dividend yield of 0.8%. Cardinal Health’s dividend payout ratio is presently 28.49%.
Cardinal Health Profile
Cardinal Health, Inc is a healthcare services and products company that supports the distribution and delivery of pharmaceuticals, medical products and related services. The company serves hospitals, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices and other healthcare providers.
Its Pharmaceutical and Specialty Solutions segment distributes branded, generic and specialty pharmaceuticals, as well as consumer health products, to pharmacies and healthcare institutions.
Read More
- Five stocks we like better than Cardinal Health
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Want to see what other hedge funds are holding CAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cardinal Health, Inc. (NYSE:CAH – Free Report).
Receive News & Ratings for Cardinal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardinal Health and related companies with MarketBeat.com's FREE daily email newsletter.
